Oxford Brain Diagnostics Ltd
Type of organisation: Medical Technology & Diagnostics
Oxford Brain Diagnostics, a spinout from the University of Oxford, has developed a novel approach (Cortical Disarray Measurement – CDM) for extracting correlates of micro-anatomy from standard MRI brain images, providing valuable information about Alzheimer’s disease (paper under review). The past eight years has seen the collaboration of two world class specialists – Dr Steven Chance (CEO), Neuroscience and Pathology and Professor Mark Jenkinson (Co-Founder), Neuroimaging. In unpublished tests, CDM has been used to classify which patients will develop Alzheimer’s and other forms of dementia within 2 – 3 years. Early results indicate promising outcomes for differential diagnosis between dementias.